Armata Pharmaceuticals (ARMP) financial statements
Net income was -$174M.
Free cash flow was -$26M.
The diluted share count rose 3583% over the period (dilution).
Income statement
Fiscal years, from Armata Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $6M | $3M | $8M | $10M | $14M | $20M | $35M | $34M | $34M | $24M |
| Selling, general and admin | $8M | $8M | $3M | $9M | $8M | $8M | $7M | $12M | $13M | $12M |
| Operating income | -$23M | -$16M | -$18M | -$20M | -$22M | -$24M | -$37M | -$41M | -$42M | -$37M |
| Interest expense | $6,000 | — | $1M | $931,000 | $628,000 | $64,000 | $0 | $3M | — | — |
| Pre-tax income | -$19M | -$14M | -$17M | -$19M | -$22M | -$23M | -$36,917 | -$69M | -$19M | -$174M |
| Income tax | -$556,000 | -$1M | -$328,000 | — | — | — | — | — | — | — |
| Net income | -$19M | -$13M | -$17M | -$19M | -$22M | -$23M | -$37M | -$69M | -$19M | -$174M |
| EPS (diluted) | -$24.67 | -$2.18 | -$3.59 | -$2.55 | -$1.35 | -$0.96 | -$1.08 | -$1.91 | -$0.89 | -$4.80 |
| Diluted shares | 1M | 7M | 5M | 8M | 16M | 24M | 34M | 36M | 59M | 36M |
Balance sheet
Fiscal years, from Armata Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $5M | $5M | $10M | $6M | $10M | $10M | $15M | $14M | $9M | $9M |
| Receivables | $12,000 | — | — | — | — | — | — | — | — | — |
| Total current assets | $6M | $5M | $10M | $7M | $11M | $15M | $27M | $19M | $11M | $11M |
| Property, plant and equipment | $1M | $816,000 | $3M | $2M | $2M | $2M | $4M | $13M | $13M | $12M |
| Goodwill | — | — | — | $3M | $3M | $3M | $3M | $3M | $3M | $3M |
| Total assets | $18M | $11M | $15M | $25M | $40M | $70M | $96M | $98M | $86M | $77M |
| Total current liabilities | $4M | $2M | $2M | $5M | $7M | $5M | $25M | $16M | $48M | $9M |
| Total liabilities | $8M | $3M | $7M | $11M | $21M | $44M | $60M | $130M | $134M | $295M |
| Shareholders' equity | $10M | $24M | $8M | $15M | $19M | $25M | $36M | -$32M | -$48M | -$219M |
| Net debt | -$5M | -$5M | -$10M | -$6M | -$10M | -$10M | -$15M | -$14M | -$9M | -$9M |
Cash flow
Fiscal years, from Armata Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11M | -$9M | -$11M | -$16M | -$18M | -$24M | -$32M | -$47M | -$38M | -$26M |
| Capital spending | $279,000 | $58,000 | $875,000 | $224,000 | $824,000 | $1M | $2M | $8M | $2M | $542,000 |
| Free cash flow | -$11M | -$9M | -$12M | -$16M | -$19M | -$25M | -$35M | -$56M | -$39M | -$26M |
| Stock-based compensation | $2M | $700,000 | $46,000 | $4M | $3M | $3M | $3M | $938,000 | $3M | $3M |
| Dividends paid | $80,000 | — | — | — | — | — | — | — | — | — |
| Dividends per share | $0.08 | — | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ARMP.
Open ARMP in InvestinglyQuestions
How much free cash flow does Armata Pharmaceuticals generate?
-$26M in fiscal 2025 (operating cash flow minus capital spending).
From Armata Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.